Study drug for advanced lung cancer with a specific EGFR change
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your lung cancer is NSCLC that is locally advanced or has spread, confirmed by pathology tests, and standard treatment is not possible or not tolerated.
- Your trial team can use a tumor sample to test for the EGFR C797S mutation in a central lab.
- You have at least one measurable tumor spot on scans, and your health/activity level is ECOG 0 to 1.
- You have expected survival of more than 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (HS-10504) compared with standard chemotherapy for people with advanced non-small cell lung cancer that has a specific genetic change called C797S and has already been treated with an EGFR inhibitor. The goal is to see if the new drug works better at shrinking or controlling the cancer.
This trial tests a new targeted drug (HS-10504) for people with advanced EGFR-mutated non-small cell lung cancer that has worsened after previous EGFR inhibitor therapy. The study aims to see if this drug can help shrink tumors or slow cancer growth.
This trial tests a new drug, HS-20117, for people with advanced solid tumors, especially certain types of lung cancer. It aims to see if the drug is safe and effective when other treatments have stopped working.
This trial tests a new drug, HSK40118, for people with advanced non-small cell lung cancer (NSCLC) that has an EGFR mutation and has been treated with certain EGFR-targeted therapies before. The goal is to see if this drug can help when other treatments stop working.
This trial tests an experimental drug called HS-10365 for people with advanced or metastatic non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug aims to block the growth of cancer cells with this mutation.
This trial tests a new study drug (HS-10504) given along with other treatments for advanced non-small cell lung cancer that has not responded to earlier therapy. The goal is to see if adding this drug can help control the cancer and shrink tumors.
Hear when a new Advanced or Metastatic NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.